- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- Brexpiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Phoenix, Arizona • San Francisco, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 13,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Post-COVID Postural Orthostatic Tachycardia Syndrome
- Interventions
- IgPro20, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
- Conditions
- Clostridoides Difficile Associated Disease
- Interventions
- C.difficile vaccine, Saline Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 32,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 142
- States / cities
- Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more
- Conditions
- Growth
- Interventions
- Control Infant Formula, Control Toddler Drink, Experimental Infant Formula, Experimental Toddler Drink, Human Milk, Human Milk Supplemental Formula, Human Milk Toddler Drink
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 607 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Glenwood, Arkansas • Hot Springs, Arkansas + 35 more
- Conditions
- Obesity
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 50
- States / cities
- Fairhope, Alabama • Beverly Hills, California • Los Angeles, California + 41 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- INNO-206
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Billings, Montana • Albany, New York + 4 more
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Reslizumab, Saline
- Biological · Other
- Lead sponsor
- Ception Therapeutics
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Diabetic Macular Edema
- Interventions
- KVD001 Injection, Sham Procedure
- Drug · Other
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more
- Conditions
- Chronic Cluster Headache
- Interventions
- ATI Neurostimulation System
- Device
- Lead sponsor
- Autonomic Technologies, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • Stanford, California + 19 more
- Conditions
- Multiple System Atrophy
- Interventions
- Rifampicin, placebo
- Drug
- Lead sponsor
- Phillip Low
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Diego, California • Jacksonville, Florida + 7 more
- Conditions
- Acute Treatment of Migraine
- Interventions
- Rimegepant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 21
- States / cities
- Canoga Park, California • Fresno, California • Los Angeles, California + 16 more
- Conditions
- Neuroblastoma
- Interventions
- carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 12 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
- Conditions
- Fabry Disease
- Interventions
- Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828), Migalastat
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 5 more
- Conditions
- Joint Discomfort, Musculoskeletal Pain, Mobility Limitation
- Interventions
- Placebo, Supplement
- Other · Dietary Supplement
- Lead sponsor
- Able Biolabs, LLC
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 25
- States / cities
- Duarte, California • Greenbrae, California • Los Angeles, California + 21 more
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
- Interventions
- ADC
- Drug
- Lead sponsor
- MBrace Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
- Conditions
- Stargardt Disease
- Interventions
- OCU410ST
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 11 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- TG4010, placebo
- Biological · Drug
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Topeka, Kansas • Louisville, Kentucky + 9 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
- Conditions
- Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Interventions
- RO7198457 intravenous (IV), Observational group (no intervention)
- Drug · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more
- Conditions
- Hereditary Angioedema
- Interventions
- Lanadelumab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Walnut Creek, California • Centennial, Colorado + 8 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Mobile, Alabama • Concord, California • Fresno, California + 48 more
- Conditions
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Interventions
- Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more